Source: CureToday articles
Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.
Recent Content
- Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
- ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
- Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
- Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
- Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
- Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
- ASH 2024: Circulating Tumor Cells Can Serve as Biomarker for Poor Outcomes in Multiple Myeloma
- ASH 2024: Expert Highlights Bolstered MRD Negativity, Survival With D-VRd in Newly-Diagnosed Multiple Myeloma
- Tecvayli Effective Maintenance Therapy in Newly Diagnosed Multiple Myeloma
- Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma